Cardiovascular Diabetology

Table 4 Physical and 2DE structural and functional parameters at 4 weeks (final)

From: The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats

	Level	Parameter	Group
	Level	Parameter	Control	Empagliflozin
		Body weight [gr]	398 ± 46	382 ± 21
Apical level	Systolic	LVESA [mm²]	52.4 ± 5.4^***	53.5 ± 5.1^***
	Systolic	LVIDs [mm]	7.9 ± 0.5^***	7.8 ± 0.5^***
	Diastolic	LVEDA [mm²]	69.3 ± 5.6^**	77.1 ± 5.3^***
	Diastolic	LVIDd [mm]	9.5 ± 0.5^**	9.0 ± 0.4^*
	Function	FS [%]	17.6 ± 4.2^**	13.7 ± 4.0^**
		FAC [%]	27.6 ± 3.8^***	31.0 ± 3.5^***
		EF [%]	37.3 ± 6.8^**	32.3 ± 6.4^**
Papillary muscles level	Systolic	LVESA [mm²]	60.6 ± 4.4^***	57.5 ± 4.0^***
	Systolic	LVIDs [mm]	8.1 ± 0.5^***	8.2 ± 0.5^***
	Diastolic	LVEDA [mm²]	89.2 ± 4.8^**	85.3 ± 4.5^***
	Diastolic	LVIDd [mm]	9.8 ± 0.3^***	9.8 ± 0.3^***
	Function	FS [%]	18.6 ± 3.4^***	17.6 ± 3.2^***
		FAC [%]	34.1 ± 3.7^**	33.5 ± 3.4^**
		EF [%]	40.1 ± 5.8^***	39.4 ± 5.4^**

Abbs. as in Table 2. * P < 0.05 vs. baseline, ** P < 0.01 vs. baseline and *** P < 0.001 vs. baseline

Back to article page

ISSN: 1475-2840

Contact us

Submission enquiries: journalsubmissions@springernature.com